urothelial carcinoma

You have access
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638
You have access
Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, KEITA IZUMI, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, TOSHIHIKO IIZUKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research February 2022, 42 (2) 1131-1136; DOI: https://doi.org/10.21873/anticanres.15576
You have access
Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy
AKINORI MINATO, HIROTSUGU NOGUCHI, RIEKO KIMURO, HARADA MIRII, NAGATA YUJIRO, YOSHITAKA HASEGAWA, IKKO TOMISAKI, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research January 2022, 42 (1) 263-269; DOI: https://doi.org/10.21873/anticanres.15481
You have access
Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers
MACIEJ KACZOROWSKI, JOANNA MATYSIAK, PAWEL KIELB, BARTOSZ MALKIEWICZ and AGNIESZKA HALON

Anticancer Research January 2022, 42 (1) 493-500; DOI: https://doi.org/10.21873/anticanres.15507
You have access
Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells
BING-SANG WONG, WEN-TUNG WU, JUI-HSIN SU, YIH-GANG GOAN and YU-JEN WU

Anticancer Research December 2021, 41 (12) 6123-6133; DOI: https://doi.org/10.21873/anticanres.15432
You have access
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma
TETSUYA YUMIOKA, MASASHI HONDA, RYUTARO SHIMIZU, SHOGO TERAOKA, NORIYA YAMAGUCHI, BUNYA KAWAMOTO, HIDETO IWAMOTO, SHUICHI MORIZANE, KATSUYA HIKITA and ATSUSHI TAKENAKA

Anticancer Research November 2021, 41 (11) 5767-5773; DOI: https://doi.org/10.21873/anticanres.15393
You have access
Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma
YOSHIFUMI KADONO, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, TAIKI KAMIJIMA, CHIKASHI SETO, AKINOBU TAKANO, SATOSHI YOTSUYANAGI, RYUNOSUKE NAKAGAWA, TOHRU MIYAGI, SHUHEI AOYAMA, HIDEKI ASAHI, RIE FUKUDA and ATSUSHI MIZOKAMI

Anticancer Research March 2021, 41 (3) 1599-1606; DOI: https://doi.org/10.21873/anticanres.14921
You have access
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
YUDAI ISHIYAMA, TSUNENORI KONDO, YUKI NEMOTO, YUKI KOBARI, HIROKI ISHIHARA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, YASUNOBU HASHIMOTO, TOSHIO TAKAGI, JUNPEI IIZUKA and KAZUNARI TANABE

Anticancer Research March 2021, 41 (3) 1607-1614; DOI: https://doi.org/10.21873/anticanres.14922
You have access
The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy
KENSHIRO TAKEMOTO, JUN TEISHIMA, YUKI KOHADA, KENICHIRO IKEDA, HIROTAKA NAGAMATSU, AKIHIRO GORIKI, SHOGO INOUE, TETSUTARO HAYASHI, MITSURU KAJIWARA and AKIO MATSUBARA

Anticancer Research August 2020, 40 (8) 4787-4793; DOI: https://doi.org/10.21873/anticanres.14481
You have access
The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer
RENATO NAITO, KOUJI IZUMI, SUGURU KADOMOTO, TOMOYUKI MAKINO, HIROAKI IWAMOTO, HIROSHI YAEGASHI, KAZUYOSHI SHIGEHARA, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI

Anticancer Research February 2020, 40 (2) 1141-1146; DOI: https://doi.org/10.21873/anticanres.14055

Main menu

User menu

Search

urothelial carcinoma

Pages